B2M and neoplasm: Although this therapy stimulates T cells by the presentation of tumor antigens by DC, helping to eliminate the effects of the loss of MHC class I surface expression in tumor cells, B2M gene defect found in this patient with aggressive clinical course and resistance to DC vaccination might partly explain the failure of the therapy.